Schizophrenia: recent advances in LC-MS/MS methods to determine antipsychotic drugs in biological samples

Author(s)

Queiroz, Maria Eugenia C. ^[1] ; Lemos Pinto, Monia Ap ^[2] ; Cruz, Jonas Carneiro ^[1] ; Ushirohira, Juliana Mayumi ^{[2, 3]} ; da Silva Dias, Isabella Caroline ^{[2, 3]} ; Hallak, Jaime E. C. ^{[2, 3]}

Affiliation

^[1] Univ Sao Paulo, Dept Quim, Ave Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Sao Paulo - Brazil

^[3] CNPQ FAPESP CAPES, Translat Med INCT TM, Natl Inst Sci & Technol, Sao Paulo - Brazil

• Document type: Review article
• Source: BIOANALYSIS; v. 11, n. 3, p. 215-231, FEB 2019.
• Web of Science Citations: 1

Abstract

Schizophrenia is one of the most debilitating and costly illnesses worldwide. First-generation antipsychotics such as chlorpromazine and haloperidol succeeded in controlling the positive symptoms of schizophrenia, but had significant extrapyramidal effects that led to the search for new agents and the release of second-generation (or atypical) antipsychotics. These drugs had a lower risk of adverse motor symptoms. Therapeutic drug monitoring has become a useful tool to optimize schizophrenia treatment and HPLC-MS/MS has been considered the primary technique to monitor antipsychotics. This review comprises three sections: schizophrenia pathophysiology and treatment; recent advances in LC-MS/MS methods designed to measure levels of antipsychotics and their metabolites in plasma samples (selectivity, matrix effect and sensitivity); and the importance of therapeutic drug monitoring. (AU)

• FAPESP's process: 17/02147-0 - Single drop chromatography and its coupling to mass spectrometry: instrumental strategies, development of materials, automation and analytical applications
• Grantee: Fernando Mauro Lanças
• Support Opportunities: Research Projects - Thematic Grants